A Phase 3 interventional study of Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection. in Ankylosing Spondylitis, sponsored by Novartis Pharmaceuticals. Completed at 10 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing secukinumab in Spondylitis, Ankylosing — 3 open to participants now, 4 under way, none of them phase 3. secukinumab · Spondylitis, Ankylosing.
Among the 20 studies testing secukinumab in Spondylitis, Ankylosing, this one is the 19th largest by enrollment, is one of 4 that started in 2016, is one of 11 in phase 3, and was the 9th registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
Browse Spondylitis, Ankylosing studies →3 of the 20 studies testing secukinumab in Spondylitis, Ankylosing are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Tongji Hospital · Sites in China
Ages 18–80
The Affiliated Hospital Of Guizhou Medical University · Sites in China
Ages 18+
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 223 across the 20 interventional studies. Of the 15 that completed or were terminated, 15 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
21 studies in Spondylitis, Ankylosing by Novartis: 2 open now, 2 under way, none of them phase 3. Of 19 finished, 17 (89%) have results posted.
Among the 21 studies in Spondylitis, Ankylosing by Novartis, this one is the 15th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2016, is one of 11 in phase 3, and was the 10th registered.
Novartis’s Spondylitis, Ankylosing studies by the year they started, since 2009.
1 of the studies testing secukinumab in Spondylitis, Ankylosing that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06833112The Affiliated Hospital Of Guizhou Medical UniversityInterleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing secukinumab in Spondylitis, Ankylosing, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 21 in Spondylitis, Ankylosing:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess the clinical efficacy, safety and tolerability of secukinumab subcutaneous injections up to 52 weeks in Japanese patients with active AS despite current or previous non-steroidal anti-inflammatory drugs (NSAIDs) and/or anti-tumor necrosis factor (TNF) α therapy. Efficacy and safety data were used to support the registration of secukinumab in Japan for the treatment of active AS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A screening (SCR) epoch running 4-10 weeks before baseline (BSL) was used to assess eligibility followed by 52 weeks of treatment. The treatment periods consist of Treatment period 1 (BSL to Week 24) and Treatment period 2 (Week 24 to Week 52). After Week 52 follows a post-treatment follow-up until Week 60. A follow-up visit was done at 12 weeks after last study treatment administration for all patients, regardless of whether they completed the entire study as planned (Week 60) or discontinue prematurely.
Drug: Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.
Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks.
Assessment of SpondyloArthritis International Society 20 Response (ASAS20)
This table is ASAS20 response using non-responder imputation for FAS It assesses the efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline in Japanese patients with active AS based on the proportion of patients achieving an ASAS (Assessment of SpondyloArthritis International Society criteria) 20 response. The ASAS Response Criteria (ASAS 20) is defined as an improvement of ≥ 20% and ≥ 1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥ 20% and ≥ 1 unit on a scale of 10 in the remaining domain
Time frame: week 16
ASAS 40 Response Rate With Non-responder Imputation (NRI)
The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients achieving an ASAS 40 response ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain
Time frame: Week 16
Bath Ankylosing Spondylitis Disease Activity (BASDAI) 50 Response Rate
The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients achieving Bath Ankylosing Spondylitis Disease Activity (BASDAI) 50 response The BASDAI 50 is defined as an improvement of at least 50% in the BASDAI compared to baseline
Time frame: Week 16
Change in High Sensitivity C-Reactive Protein (hsCRP)
hsCRP (mg/L) change from baseline using observed data with log e transformation The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline of high sensitivity C-Reactive Protein (hsCRP) hsCRP is measured as a marker of inflammation from blood samples during the study
Time frame: baseline, Week 16
Number of Participants With ASAS 5/6 Response Criteria
The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients meeting the ASAS 5/6 response criteria The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains
Time frame: Week 16
Mean Change From Baseline in BASDAI From Baseline
The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline in total BASDAI The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue (0 being no problem and 10 being the worst problem) in response to six questions asked of the patient pertaining to the five major symptoms of AS Each question (question 1 to 6) is scored from 0 to 10 (0 being no problem and 10 being the worst problem). To give each symptom equal weighting, the mean (average) of the two scores relating to morning stiffness (questions 5 and 6) is taken. The mean of questions 5 and 6 is added to the scores from questions 1-4. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score.
Time frame: Baseline, week 16
Change From Baseline in Short Form Health Survey Physical Component Summary (SF-36 PCS) Score
SF-36 PCS, mean change from baseline: The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline in Short Form Health Survey Physical Component Summary (SF-36 PCS) The SF-36 is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions Score range is from 0 (no problems) to 100 (unable to perform the activity) SF-36 is a 36 item questionnaire which measures Quality of Life across eight domains, which are both physically and emotionally based. Two overall summary scores, the Physical Component Summary (PCS) and Mental Component Summary (MCS) can be computed. In this study, SF-36 PCS is used to assess improvement from baseline. There is no total overall score; scoring is computed for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score.
Time frame: Baseline, week 16
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score
The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline in Ankylosing Spondylitis Quality of Life (ASQoL) The ASQoL is a self-administered questionnaire designed to assess health-related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each "yes" response and no points for each "no" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity)
Time frame: Baseline, week 16
Proportion of Participants Achieving ASAS Partial Remission
The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients achieving an ASAS partial remission The ASAS partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10
Time frame: week 16
Change in Serum Concentration of Secukinumab
The assessment of pre dose concentration of secukinumab in Japanese AS patients An enzyme-linked immunosorbent assay (ELISA) method will be used for bioanalytical analysis of secukinumab in serum, with an anticipated lower limit of quantification (LLOQ) of 80 ng/mL.
Time frame: Baseline, weeks 4, 16, 24, 52, 60
Number of Participants With Immunogenicity Against Secukinumab
Concentration of anti-secukinumab antibodies Assessment of immunogenicity against secukinumab by concentration of anti-secukinumab antibodies at pre-dose. An electrochemiluminescence method was used for the detection of potential anti-secukinumab antibody formation.
Time frame: week 60
Number of Participants With Newly Occurring or Worsening Hematology Abnormalities Based on CTCAE Grade, Blood
Common Terminology Criteria for Adverse Events (CTCAE) Grades 1-5 refer to severity of the AE: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL)\*. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL\*\*. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. \*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc. \*\*Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.
Time frame: week 60
Number of Participants With Newly Occurring or Worsening Chemistry Abnormalities Based on CTCAE Grade
Common Terminology Criteria for Adverse Events (CTCAE) Grades 1-5 refer to severity of the AE: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL)\*. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL\*\*. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. \*Instrumental ADL include preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc. \*\*Self care ADL include bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.
Time frame: week 60
Participants With Newly Occurring or Worsening Liver Enzyme Abnormalities
During the entire safety reporting period, mean values of each liver enzyme parameter stayed within the normal range and were comparable to the baseline values ALP=Alkaline phosphatase ALT=Alanine aminotransferase AST=Aspartate aminotransferase TBL=Total bilirubin ULN=Upper Limit Normal
Time frame: week 60
Number of Participants With Newly Occurring or Worsening Lipid Parameters Abnormalities
During the entire safety reporting period, mean values of each lipid parameter stayed within the normal range and were comparable to the baseline values
Time frame: week 60
Participants With Newly Occurring Notable Abnormalities in Vital Signs
Sitting Pulse (bpm) High only (\> 100 bpm) Low only (\< 60 bpm) Low and High (\< 60 bpm and \> 100 bpm) Sitting Diastolic Blood Pressure (BP) (mmHg) High only (≥ 90 mmHg) Low only (\< 60 mmHg) Low and High (\< 60 mmHg and ≥ 90 mmHg) Sitting Systolic Blood Pressure (mmHg) High only (≥ 140 mmHg) Low only (\< 90 mmHg) Low and High (\< 90 mmHg and ≥ 140 mmHg)
Time frame: week 60
A total of 37 patients were screened, and 30 patients (81.1%) completed the screening phase and entered Treatment Period
| Milestone | Secukinumab 150mg |
|---|---|
| Started | 30 |
| Completed | 25 |
| Not completed | 5 |
| Withdrew: Adverse event | 3 |
| Withdrew: Lack of efficacy | 2 |
This table is ASAS20 response using non-responder imputation for FAS It assesses the efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline in Japanese patients with active AS based on the proportion of patients achieving an ASAS (Assessment of SpondyloArthritis International Society criteria) 20 response. The ASAS Response Criteria (ASAS 20) is defined as an improvement of ≥ 20% and ≥ 1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥ 20% and ≥ 1 unit on a scale of 10 in the remaining domain
| participants | Secukinumab 150mg |
|---|---|
| Assessment of SpondyloArthritis International Society 20 Response (ASAS20) | 21 |
The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients achieving an ASAS 40 response ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain
| participants | Secukinumab 150mg |
|---|---|
| ASAS 40 Response Rate With Non-responder Imputation (NRI) | 14 |
The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients achieving Bath Ankylosing Spondylitis Disease Activity (BASDAI) 50 response The BASDAI 50 is defined as an improvement of at least 50% in the BASDAI compared to baseline
| participants | Secukinumab 150mg |
|---|---|
| Bath Ankylosing Spondylitis Disease Activity (BASDAI) 50 Response Rate | 11 |
hsCRP (mg/L) change from baseline using observed data with log e transformation The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline of high sensitivity C-Reactive Protein (hsCRP) hsCRP is measured as a marker of inflammation from blood samples during the study
| mg/L | Secukinumab 150mg |
|---|---|
| Change in High Sensitivity C-Reactive Protein (hsCRP) | 0.247 (0.125 to 0.487) |
The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients meeting the ASAS 5/6 response criteria The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains
| participants | Secukinumab 150mg |
|---|---|
| Number of Participants With ASAS 5/6 Response Criteria | 14 |
The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline in total BASDAI The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue (0 being no problem and 10 being the worst problem) in response to six questions asked of the patient pertaining to the five major symptoms of AS Each question (question 1 to 6) is scored from 0 to 10 (0 being no problem and 10 being the worst problem). To give each symptom equal weighting, the mean (average) of the two scores relating to morning stiffness (questions 5 and 6) is taken. The mean of questions 5 and 6 is added to the scores from questions 1-4. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score.
| scores on a scale | Secukinumab 150mg |
|---|---|
| Mean Change From Baseline in BASDAI From Baseline | -3.088 ± 2.0697 |
SF-36 PCS, mean change from baseline: The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline in Short Form Health Survey Physical Component Summary (SF-36 PCS) The SF-36 is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions Score range is from 0 (no problems) to 100 (unable to perform the activity) SF-36 is a 36 item questionnaire which measures Quality of Life across eight domains, which are both physically and emotionally based. Two overall summary scores, the Physical Component Summary (PCS) and Mental Component Summary (MCS) can be computed. In this study, SF-36 PCS is used to assess improvement from baseline. There is no total overall score; scoring is computed for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score.
| scores on a scale | Secukinumab 150mg |
|---|---|
| Change From Baseline in Short Form Health Survey Physical Component Summary (SF-36 PCS) Score | 6.306 ± 8.0724 |
The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline in Ankylosing Spondylitis Quality of Life (ASQoL) The ASQoL is a self-administered questionnaire designed to assess health-related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each "yes" response and no points for each "no" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity)
| scores on a scale | Secukinumab 150mg |
|---|---|
| Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score | -3.40 ± 4.00 |
The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients achieving an ASAS partial remission The ASAS partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10
| participants | Secukinumab 150mg |
|---|---|
| Proportion of Participants Achieving ASAS Partial Remission | 6 ± 20.0 |
The assessment of pre dose concentration of secukinumab in Japanese AS patients An enzyme-linked immunosorbent assay (ELISA) method will be used for bioanalytical analysis of secukinumab in serum, with an anticipated lower limit of quantification (LLOQ) of 80 ng/mL.
| μg/mL | Secukinumab 150mg |
|---|---|
| week 4 | 51.3 ± 15.35 |
| week 16 | 25.0 ± 10.19 |
| week 24 | 22.2 ± 8.96 |
| week 52 | 21.1 ± 6.08 |
| week 60 | 6.2 ± 3.61 |
Concentration of anti-secukinumab antibodies Assessment of immunogenicity against secukinumab by concentration of anti-secukinumab antibodies at pre-dose. An electrochemiluminescence method was used for the detection of potential anti-secukinumab antibody formation.
| participants | Secukinumab 150mg |
|---|---|
| Number of Participants With Immunogenicity Against Secukinumab | 0 |
Common Terminology Criteria for Adverse Events (CTCAE) Grades 1-5 refer to severity of the AE: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL)\*. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL\*\*. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. \*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc. \*\*Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.
| participants | Secukinumab 150mg |
|---|---|
| Hemoglobin (g/L) <LLN - 100 g/L (Grade1) | 6 |
| Hemoglobin (g/L) <100 - 80 g/L (Grade2) | 0 |
| Hemoglobin (g/L) < 80g/L (Grade3) | 0 |
| Lymphocytes (10E9/L) <LLN - 0.8 × 10e9/L (Grade1) | 2 |
| Lymphocytes (10E9/L) <0.8 - 0.5 × 10e9/L (Grade2) | 1 |
| Lymphocytes (10E9/L) <0.5 - 0.2 × 10e9/L (Grade3) | 1 |
| Lymphocytes (10E9/L) <0.2 × 10e9/L (Grade4) | 0 |
| Neutrophils (10E9/L) < LLN - 1.5 × 10e9/L (Grade1) | 0 |
| Neutrophils (10E9/L) < 1.5 - 1.0 × 10e9/L (Grade2) | 1 |
| Neutrophils (10E9/L) < 1.0 - 0.5 × 10e9/L (Grade3) | 0 |
| Neutrophils (10E9/L) < 0.5 × 10e9/L (Grade4) | 0 |
| Platelets (10E9/L) <LLN - 75.0 ×10e9/L (Grade1) | 3 |
| Platelets (10E9/L) <75.0 - 50.0 ×10e9/L (Grade2) | 0 |
| Platelets (10E9/L) <50.0 - 25.0 ×10e9/L (Grade3) | 0 |
| Platelets (10E9/L), Blood <25.0 ×10e9/L (Grade4) | 0 |
| Leukocytes (10E9/L) <LLN - 3.0 × 10e9/L (Grade1) | 0 |
| Leukocytes (10E9/L) <3.0 - 2.0 × 10e9/L (Grade2) | 1 |
| Leukocytes (10E9/L) <2.0 - 1.0 × 10e9/L (Grade3) | 0 |
| Leukocytes (10E9/L) <1.0 × 10e9/L (Grade4) | 0 |
Common Terminology Criteria for Adverse Events (CTCAE) Grades 1-5 refer to severity of the AE: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL)\*. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL\*\*. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. \*Instrumental ADL include preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc. \*\*Self care ADL include bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.
| participants | Secukinumab 150mg |
|---|---|
| Alkaline Phosphatase (U/L), Serum (Grade1) | 3 |
| Alkaline Phosphatase (U/L), Serum (Grade2) | 0 |
| Alkaline Phosphatase (U/L), Serum (Grade3) | 0 |
| Alkaline Phosphatase (U/L), Serum (Grade4) | 0 |
| Alanine Aminotransferase (U/L), Serum (Grade1) | 3 |
| Alanine Aminotransferase (U/L), Serum (Grade2) | 0 |
| Alanine Aminotransferase (U/L), Serum (Grade3) | 0 |
| Alanine Aminotransferase (U/L), Serum (Grade4) | 0 |
| Aspartate Aminotransferase (U/L), Serum (Grade1) | 4 |
| Aspartate Aminotransferase (U/L), Serum (Grade2) | 0 |
| Aspartate Aminotransferase (U/L), Serum (Grade3) | 0 |
| Aspartate Aminotransferase (U/L), Serum (Grade4) | 0 |
| Bilirubin (umol/L), Serum (Grade1) | 2 |
| Bilirubin (umol/L), Serum (Grade2) | 1 |
| Bilirubin (umol/L), Serum (Grade3) | 0 |
| Bilirubin (umol/L), Serum (Grade4) | 0 |
| Cholesterol (mmol/L), Serum (Grade1) Serum | 4 |
| Cholesterol (mmol/L), Serum (Grade2) | 0 |
| Cholesterol (mmol/L), Serum (Grade3) | 0 |
| Cholesterol (mmol/L), Serum (Grade4) | 0 |
| Creatinine (umol/L), Plasma/Serum (Grade1) | 1 |
| Creatinine (umol/L), Plasma/Serum (Grade2) | 0 |
| Creatinine (umol/L), Plasma/Serum (Grade3) | 0 |
| Creatinine (umol/L), Plasma/Serum (Grade4) Serum | 0 |
| Gamma Glutamyl Transferase (U/L), Serum (Grade1) | 1 |
| Gamma Glutamyl Transferase (U/L), Serum (Grade2) | 0 |
| Gamma Glutamyl Transferase (U/L), Serum (Grade3) | 0 |
| Gamma Glutamyl Transferase (U/L), Serum (Grade4) | 0 |
| Glucose Decreased (mmol/L), Plasma (Grade1) | 0 |
| Glucose Decreased (mmol/L), Plasma (Grade2) | 0 |
| Glucose Decreased (mmol/L), Plasma (Grade3) | 0 |
| Glucose Decreased (mmol/L), Plasma (Grade4) | 0 |
| Glucose Increased (mmol/L), Plasma (Grade1) | 12 |
| Glucose Increased (mmol/L), Plasma (Grade2) | 3 |
| Glucose Increased (mmol/L), Plasma (Grade3) | 1 |
| Glucose Increased (mmol/L), Plasma (Grade4) | 0 |
| Triglycerides (mmol/L), Plasma/Serum (Grade1) | 9 |
| Triglycerides (mmol/L), Plasma/Serum (Grade2) | 1 |
| Triglycerides (mmol/L), Plasma/Serum (Grade3) | 0 |
| Triglycerides (mmol/L), Plasma/Serum (Grade4) | 0 |
During the entire safety reporting period, mean values of each liver enzyme parameter stayed within the normal range and were comparable to the baseline values ALP=Alkaline phosphatase ALT=Alanine aminotransferase AST=Aspartate aminotransferase TBL=Total bilirubin ULN=Upper Limit Normal
| participants | Secukinumab 150mg |
|---|---|
| ALT > 3 × ULN | 0 |
| ALT > 5 × ULN | 0 |
| ALT > 8 × ULN | 0 |
| ALT > 10 × ULN | 0 |
| ALT > 20 × ULN | 0 |
| AST > 3 × ULN | 0 |
| AST > 5 × ULN | 0 |
| AST > 8 × ULN | 0 |
| AST > 10 × ULN | 0 |
| AST > 20 × ULN | 0 |
| ALT or AST > 3 × ULN | 0 |
| ALT or AST > 5 × ULN | 0 |
| ALT or AST > 8 × ULN | 0 |
| ALT or AST > 10 × ULN | 0 |
| ALT or AST > 20 × ULN | 0 |
| TBL > 1.5 × ULN | 1 |
| TBL > 2 × ULN | 0 |
| TBL > 3 × ULN | 0 |
| ALP > 2 × ULN | 0 |
| ALP > 3 × ULN | 0 |
| ALP > 5 × ULN | 0 |
| ALT or AST > 3 × ULN & TBL > 2 × ULN | 0 |
| ALT or AST > 5 × ULN & TBL > 2 × ULN | 0 |
| ALT or AST > 8 × ULN & TBL > 2 × ULN | 0 |
| ALT or AST > 10 × ULN & TBL > 2 × ULN | 0 |
| ALP > 3 × ULN & TBL > 2 × ULN | 0 |
| ALP > 5 × ULN & TBL > 2 × ULN | 0 |
| ALT or AST> 3 × ULN & TBL> 2 × ULN & ALP <2 × ULN | 0 |
During the entire safety reporting period, mean values of each lipid parameter stayed within the normal range and were comparable to the baseline values
| participants | Secukinumab 150mg |
|---|---|
| HDL: ≤ LLN | 5 |
| HDL: < 0.8 × LLN | 1 |
| LDL: ≥ ULN | 1 |
| LDL: > 1.5 × ULN | 0 |
| LDL: > 2.5 × ULN | 0 |
| Cholesterol: ≥ ULN | 4 |
| Cholesterol: > 1.5 × ULN | 0 |
| Cholesterol: > 2.5 × ULN | 0 |
| Triglycerides: ≥ ULN | 8 |
| Triglycerides: > 1.5 × ULN | 4 |
| Triglycerides: > 2.5 × ULN | 0 |
Sitting Pulse (bpm) High only (\> 100 bpm) Low only (\< 60 bpm) Low and High (\< 60 bpm and \> 100 bpm) Sitting Diastolic Blood Pressure (BP) (mmHg) High only (≥ 90 mmHg) Low only (\< 60 mmHg) Low and High (\< 60 mmHg and ≥ 90 mmHg) Sitting Systolic Blood Pressure (mmHg) High only (≥ 140 mmHg) Low only (\< 90 mmHg) Low and High (\< 90 mmHg and ≥ 140 mmHg)
| participants | Secukinumab 150mg |
|---|---|
| Sitting Pulse (bpm) High only | 2 |
| Sitting Pulse (bpm) Low only | 5 |
| Sitting Pulse (bpm) Low and High | 0 |
| Sitting Diastolic BP (mmHg), High only | 8 |
| Sitting Diastolic BP (mmHg), Low only | 5 |
| Sitting Diastolic BP (mmHg), Low and high | 0 |
| Sitting Systolic BP (mmHg) High only | 12 |
| Sitting Systolic BP (mmHg) Low only | 0 |
| Sitting Systolic BP (mmHg) Low and High | 0 |
Collected over AEs and SAEs were collected for the maximum duration of treatment and follow up for a participant per protocol for approximately 60 weeks. All cause mortality (deaths) was collected from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) up to a maximum of 60 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AIN457 150mg | 0/30 (0%) | 3/30 (10%) | 26/30 (86.7%) |
| Event | AIN457 150mg |
|---|---|
| Coronary artery occlusionCardiac disorders | 1/30 |
| Adenocarcinoma of the cervixNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/30 |
| Drug eruptionSkin and subcutaneous tissue disorders | 1/30 |
| Event | AIN457 150mg |
|---|---|
| NasopharyngitisInfections and infestations | 15/30 |
| StomatitisGastrointestinal disorders | 7/30 |
| InfluenzaInfections and infestations | 5/30 |
| GastroenteritisInfections and infestations | 3/30 |
| LeukopeniaBlood and lymphatic system disorders | 2/30 |
| DiarrhoeaGastrointestinal disorders | 2/30 |
| PyrexiaGeneral disorders | 2/30 |
| BronchitisInfections and infestations | 2/30 |
| Infected dermal cystInfections and infestations | 2/30 |
| PharyngitisInfections and infestations | 2/30 |
The safety set included all patients who took at least one dose of study treatment during the treatment periods.
| Age, Continuous(years) | Secukinumab 150mg |
|---|---|
| Mean | 44.0 ± 13.25 |
| Age, Customized(Participants) | Secukinumab 150mg |
|---|---|
| <65 years | 27 |
| >=65years | 3 |
| >=75 years | 0 |
| Sex: Female, Male(Participants) | Secukinumab 150mg |
|---|---|
| Female | 10 |
| Male | 20 |
| Race/Ethnicity, Customized(participants) | Secukinumab 150mg |
|---|---|
| Asian | 30 |
| Other | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Mar 2016 to primary completion in Jul 2017, 15 months.
Results were first posted in Sep 2019, 2 years 2 months after primary completion.
Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 15 months is below that.
Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab